Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of new insulin glargine formulation versus Lantus in type 1 diabetes (morning vs evening injection)
2012-001524-35Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin glargine in diabetes mellitus type 1 (T1D) (4 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c. Started Aug 2012; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2012-001524-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001524-35.